Identification of a novel cell type-specific intronic enhancer of macrophage migration inhibitory factor (MIF) and its regulation by mithramycin

E. Beaulieu,*† L. Green,† L. Elsby,*† Z. Alourfi,† E. F. Morand,‡ D. W. Ray† and R. Donn*†

*ARC Epidemiology Unit, †Endocrine Sciences, Manchester Academy of Health Sciences, University of Manchester, Manchester, UK, and ‡Centre for Inflammatory Disease, Monash University, Department of Medicine, Monash Medical Centre, Melbourne, VIC, Australia

Summary

The aim of this study was to determine the genetic regulation of macrophage migration inhibitory factor (MIF). DNase I hypersensitivity was used to identify potential hypersensitive sites (HS) across the MIF gene locus. Reporter gene assays were performed in different human cell lines with constructs containing the native or mutated HS element. Following phylogenetic and transcription factor binding profiling, electrophoretic mobility shift assay (EMSA) and RNA interference were performed and the effects of incubation with mithramycin, an antibiotic that binds GC boxes, were also studied. An HS centred on the first intron of MIF was identified. The HS acted as an enhancer in human T lymphoblasts (CEMC7A), human embryonic kidney cells (HEK293T) and human monocytic cells (THP-1), but not in a fibroblast-like synoviocyte (FLS) cell line (SW982) or cultured FLS derived from rheumatoid arthritis (RA) patients. Two cis-elements within the first intron were found to be responsible for the enhancer activity. Mutation of the consensus Sp1GCGbox cis-element abrogated enhancer activity and EMSA indicated Sp1 binding to one of the cis-elements contained in the intron. SiRNA knock-down of Sp1 alone or Sp1 and Sp3 together was incomplete and did not alter the enhancer activity. Mithramycin inhibited expression of MIF in CEMC7A cells. This effect was specific to the intronic enhancer and was not seen on the MIF promoter. These results identify a novel, cell type-specific enhancer of MIF. The enhancer appears to be driven by Sp1 or related Sp family members and is highly sensitive to inhibition via mithramycin.

Keywords: gene regulation, inflammation, MIF, mithramycin

Introduction

Macrophage migration inhibitory factor (MIF) is an early modulator of inflammation and is active in both innate and adaptive immunity [1–3]. Although its role as a direct cytokine is not entirely resolved [4], the case for MIF as an important modulator of inflammation is increasingly strong. Rheumatoid arthritis (RA) is a chronic inflammatory disease of unknown aetiology affecting ~1% of the world’s population. It is characterized by progressive destruction of synovial joints. A substantial body of evidence supports a key role for MIF in RA. Multiple different animal models show a role of MIF in the inflammatory joint process [5–9]. Furthermore, elevated levels of MIF have been shown in RA synovial fluid and serum samples, compared to healthy and osteoarthritic controls [10,11]. MIF stimulates macrophage release of tumour necrosis factor (TNF)-α, interleukin (IL)-1, IL-6 and IL-8, all of which occur at increased levels in RA patients. RA fibroblast-like synoviocyte (FLS)-derived MIF induces monocyte TNF-α production in vitro [10], and MIF up-regulates FLS IL-1 mRNA expression [12]. In addition to MIF’s role as a potential upstream regulator of synovial cytokine expression, MIF contributes to the processes involved in synovial joint destruction: MIF induces metalloproteinases (MMP)-1 (interstitial collagenase) and MMP-3 (stromelysin) in FLS [12]. Murine osteoblasts express high levels of MIF [13]. MIF stimulates MMP-9 (gelatinase B) and MMP-13 (collagenase 3) from rat calvarial osteoblasts [13] and RA FLS induction of MMP-2 by MIF has also been described [14]. MIF-DNA vaccine protects from ovariectomy-induced bone loss [15] and MIF transgenic mice have high turnover osteoporosis associated with
increased MMP-3, 9 and 13 expression [16]. This cumulative work supports the involvement of MIF in the cartilage damage and bone remodelling that is central to the progressive joint destruction that occurs in RA.

MIF has an unusual relationship with glucocorticoids (Gc) acting as a counter-regulator as well as being found, in some studies, to be induced by them [7,17–20]. Despite the use of new biological disease-modifying drugs, more than half of patients with RA are treated with Gc [18]. The metabolic side effects of Gc cause considerable morbidity, especially with long-term use, as occurs in RA. Steroid-sparing therapies, such as those that limit elevation of MIF expression, would therefore be clinically advantageous.

The MIF gene is situated on chromosome 22q11.2 within a cytosine–guanine–dinucleotide (CpG) island, and is highly conserved (90%) between mammalian species [21]. The MIF promoter is GC-rich and has no TATA box, suggesting the presence of other regulatory elements. Despite MIF being a key modulator of RA aetiopathogenesis, little is currently known about MIF gene regulation. Baugh et al. [22], Welford et al. [23] and Elsby [24] have shown MIF to be regulated via the hypoxia inducible transcription factor (HIF-1), and previous work found regulation of the proximal MIF promoter by cyclic AMP response element binding protein [25]. There is also evidence demonstrating the cell type-specific inhibition of MIF gene expression by Gc [20]. Importantly, MIF, unlike other proinflammatory mediators, is not regulated by TNF-α [24]. The aim of this study was therefore to identify functional regulatory elements for the MIF gene, so allowing identification of factors important in the control of MIF expression. Using an unbiased DNase I hypersensitivity approach, we have identified a novel cell type-specific enhancer within the first intron of MIF. Further characterization of the enhancer demonstrated that it was physiologically relevant and that regulation of the enhancer with the antibiotic mithramycin resulted in repression of MIF expression.

Materials and methods

Cell lines

CEMC7A, a human T lymphoblast cell line, THP-1, a monocytic cell line and RA FLS were cultured in RPMI-1640 (GIBCO PRL, Paisley, UK) with 10% fetal bovine serum (FBS) (PerBio; Sigma, Poole, UK). RA FLS were isolated and cultured as described previously [10] and used between passages 4 and 8. The human fibroblast-like synovioocytes cell line (SW982) was cultured in I–15 Leibovitch (GIBCO) with 10% FBS. Human lung carcinoma cells (A549) and kidney cells (HEK293T) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with Glutamax (GIBCO) with 10% FBS (PerBio). All cell lines were grown in a 37°C incubator with 5% CO2. THP-1, A549, HEK293T and SW982 were obtained from the American Type Culture Collection (ATCC); CEMC7A was kindly provided by Dr Ged Brady.

Generation of probes

All polymerase chain reactions (PCR) were performed on a PTC-0225 DNA Engine Tetrad Thermal cycler (MJ Research, Waltham, MA, USA). Sequence for the probe was acquired via a search for MIF DNA on the UCSC Genome Bioinformatics website (http://genomics.ucsc.edu/). Sequence was verified for specificity using BLAST on the National Center for Biotechnology Information (NCBI) website (http://www.ncbi.nlm.nih.gov/BLAST/) and a 465 base pairs (bp) sequence was chosen to target the 5′ end of the 10-kb DNA fragment containing the MIF gene. This fragment was generated by BglII restriction digest of human genomic DNA. The probe was generated by PCR forward: 5′-GGAG GTAAAGGTCAGGAGG-3′, probe 4 reverse 5′-GTGTTCA CCTGACATAGAGG-3′ primers. The PCR product was then cloned into pCR®4Blunt-TOPO (Invitrogen, Paisley, UK). Probe sequence was confirmed by sequencing using the same primer as for PCR.

DNase I hypersensitivity assay

Confluent cells (~106 cells) were washed four times with cold phosphate-buffered saline (PBS) and then pelleted. Cells were lysed in 20 ml 1× reticulocyte standard buffer (RSB) buffer (10 mM Tris pH7-4, 10 mM NaCl, 3 mM MgCl2) with 0.1% NP-40 for 7–10 min and the nuclei pelleted. Nuclei were washed in 20 ml of 1× RSB only, pelleted at 783 g for 5 min and resuspended in a final volume of 1 ml of 1× RSB. Different concentrations of DNase I (Worthington, Lakewood, NJ, USA) were added to each tube (0, 0.3, 1, 3, 10, 30 and 100 μg/ml) and incubated at 37°C for 10 min. DNA samples were stored immediately at −20°C or purified with DNeasy columns (Qiagen, Crawley, UK) as per the manufacturer’s instructions. Ten μg of each isolated DNA sample was digested with Bgl II (Roche, Burgess Hill, UK) at 37°C overnight. Samples were then run on agarose or stored at 4°C.

Southern blotting

DNA was resolved on 0.8% 1× Tris–borate–ethylenediamine tetraacetic acid (EDTA) (TBE) agarose and transferred onto Hybond+ membrane (Amersham, Little Chalfont, Buckinghamshire, UK). Probes were labelled with [α-32P]dCTP using Random Primers DNA Labelling System (Invitrogen) according to the manufacturer’s instructions. Labelled DNA was cleaned up using a microspin G50 column (Amersham), boiled for 5 min, then added to the prehybridization buffer and left to hybridize overnight at 65°C. Membranes were then washed twice for a minimum of 10 min in 2× saline sodium citrate (SSC), 0.1% sodium dodecyl sulphide (SDS) at 65°C and autoradiography performed.
Table 1. Tiled ~50 base pairs overlapping oligonucleotide constructs designed across migration inhibitor factor (MIF) intron 1.

| oligo1       | 5′-GATCCGGTGTGCGCGGCGAGAAGGAGGGGGGCGCTGGC-3′ |
| oligo1comp   | 3′-GGATCGGCTGCGCGGCGAGAAGGAGGGGGGCGCTGGC-5′ |
| oligo2       | 5′-GATCCGGGCCGAGAAGGAGGGGGGCGCTGGC-3′ |
| oligo2comp   | 3′-GGATCGGCTGCGCGGCGAGAAGGAGGGGGGCGCTGGC-5′ |
| oligo3       | 5′-GATCGGTGTGCGCGGCGAGAAGGAGGGGGGCGCTGGC-3′ |
| oligo3comp   | 3′-GGATCGGCTGCGCGGCGAGAAGGAGGGGGGCGCTGGC-5′ |
| oligo4       | 5′-GATCCTCGGCGGCGAGAAGGAGGGGGGCGCTGGC-3′ |
| oligo4comp   | 3′-GGATCGGCTGCGCGGCGAGAAGGAGGGGGGCGCTGGC-5′ |
| oligo5       | 5′-GATCCTCGGCGGCGAGAAGGAGGGGGGCGCTGGC-3′ |
| oligo5comp   | 3′-GGATCGGCTGCGCGGCGAGAAGGAGGGGGGCGCTGGC-5′ |
| oligo6       | 5′-GATCCTCGGCGGCGAGAAGGAGGGGGGCGCTGGC-3′ |
| oligo6comp   | 3′-GGATCGGCTGCGCGGCGAGAAGGAGGGGGGCGCTGGC-5′ |
| oligo7       | 5′-GATCCTCGGCGGCGAGAAGGAGGGGGGCGCTGGC-3′ |
| oligo7comp   | 3′-GGATCGGCTGCGCGGCGAGAAGGAGGGGGGCGCTGGC-5′ |
| oligo1mut    | 5′-GATCCTCGGCGGCGAGAAGGAGGGGGGCGCTGGC-3′ |
| oligo1mutcomp| 3′-GGATCGGCTGCGCGGCGAGAAGGAGGGGGGCGCTGGC-5′ |
| oligo6mut    | 5′-GATCCTCGGCGGCGAGAAGGAGGGGGGCGCTGGC-3′ |
| oligo6mutcomp| 3′-GGATCGGCTGCGCGGCGAGAAGGAGGGGGGCGCTGGC-5′ |

Comp: complementary sequence.

Generation of reporter constructs

The whole of MIF intron 1 (194 bp) was amplified by PCR using the following primers: forward primer 5′-GGATCCGGTGTGCGCGGCGAGAAGGAGGGGGGCGCTGGC-3′ and reverse primer 3′-GGATCGGCTGCGCGGCGAGAAGGAGGGGGGCGCTGGC-5′. The amplimers were cloned initially into pBLUNT vector (Invitrogen), subcloned into pGL3-promoter vector (Promega, Southampton, UK) and then sequenced, and for each construct a clone with the intron in the sense (S) or anti-sense (AS) orientation was isolated. These were digested with XhoI and HindIII to open up the promoter site and replace the SV40 promoter with the MIF promoter region. MIF promoter was obtained by digesting the pGL3-enhancer/MIF promoter/intron SNP AS using the XhoI and HindIII sites. The gel-purified promoter was then ligated into pGL3-promoter/intron WT AS, pGL3-promoter/intron single nucleotide polymorphism (SNP) S and pGL3-promoter/intron SNP AS using the XhoI and HindIII sites.

Tiled oligonucleotide constructs

Overlapping WT (Metabion, Martinsried, Germany) or mutated oligonucleotides (Invitrogen), each ~50 bp and spanning the whole of MIF intron 1 (oligo1–oligo7), were designed and phosphorylated at the 5′ end. The sequences are given in Table 1. Complementary oligonucleotides were annealed and ligated into the pGL3 promoter vector using the BamHI sites. All plasmids were sequenced.

Transfection of plasmid DNA

Cells were transfected transiently in triplicate using either electroporation, Lipofectamine 2000 (Invitrogen) or nucleofection. For electroporation, CEMC7A and THP-1 cells were resuspended in serum-free medium at 10^6 cells per ml. Plasmid DNA (10 μg) was added with renilla (1 μg) as transfection efficiency control. Lipofectamine 2000 was used for SW982, HEK293T and CEMC7A cells. Plasmid DNA (0.2–1.5 μg) and renilla control (0.2–0.8 μg) were used for each transfection in a 96-well or a 24-well plate. HEK293T and SW982 were seeded at 2 x 10^3 cells/ml and CEM cells at 5 x 10^4 cells/ml to 3 x 10^5 cells/ml and left to grow overnight. Transfections were performed as per the manufacturer’s instructions. For nucleofection, CEMC7A were resuspended in medium at 5 x 10^5 cells/ml and grown overnight. Using the nucleofector Kit V, a total of 1 x 10^6 cells/ml was used per reaction to co-transfect siRNA with plasmid DNA with the program C16. For human RA FLS, a total of 0.5 x 10^6 cells were used per reaction to transfect 2.5 μg of plasmid DNA with the program U23 using the nucleofection kit for NHLF (Amaza, Wokingham, Berkshire, UK). Transfections were performed according to the manufacturer’s protocol.

All luciferase/renilla assays were performed 24 h post-transfection as described previously, and the normalized luciferase data presented [26].

SP1 knock-down

A pool of four siRNA sequences directed against Sp1 (M-026959-00 siGENOME SMARTpool reagent; Dharmacon, Lafayette, CO, USA) or lamin A/C control (D-001620-02-05 siGLO lamin A/C; Dharmacon) as a negative control were co-transfected with plasmid DNA (SV40/MIF intron WT S and SV40 promo) in HEK293T and CEMC7A, according to the manufacturer’s instructions. Transfections were performed in 24-well plates by nucleofection for CEMC7A or using Lipofectamine 2000 (Invitrogen) for HEK293T. iRNA (100 nM) and plasmid DNA (1–5 μg) were transfected, cells
were incubated for 48 h and each reaction was split into three fractions; Sp1 knock-down was assessed by Western blot and enhancer activity was assessed by luciferase assay.

**SP1 and SP3 combined knock-down**

HEK293T cells were co-transfected with siRNA directed against Sp1 (s8222; Ambion) (15 nM) and Sp3 (s13326, Ambion) (15 nM) or lamin A/C (s58222; Ambion) (30 nM). Transfections were performed in 24-well plates using Lipofectamine™ RNAiMAX Transfection Reagent (Invitrogen) as per the manufacturer’s instructions and incubated at 37°C for 24 h before harvesting.

**Western blotting**

Cell lysates were separated by SDS-polyacrylamide gel electrophoresis (PAGE) using either 4–20% gradient precast gels (Biorad, Hemel Hempstead, UK) in 1× Tris–glycine SDS (TGS) buffer (Biorad) or Nupage® Novex 3–8% Tris–acetate precast gels (Invitrogen) in 1× Tris–acetate running buffer (50 mM Trisbase, 50 mM Tricine, 0-4% SDS). Proteins were transferred onto supported nitocellulose (Biorad) or polyvinylidene difluoride (PVDF) membrane (Biorad), respectively. Membranes were blocked with 2% milk in PBS/0-05% Tween-20 overnight and incubated with primary antibody for 2 h followed by secondary antibodies conjugated to horseradish peroxidase (HPP) (1:1000–1:3000 dilution). Chemiluminescent results were obtained with ECL Plus (Amersham), according to the manufacturer’s protocol. Washes were performed with PBS/0-05% Tween-20. Antibodies used were as follows: anti-Sp1 rabbit antibody [1:3000; Upstate 07-645, Upstate (Millipore), Watford, UK], anti-Sp3 D-20 rabbit antibody (1:200; Santa Cruz SC-644, Santa Cruz, CA, USA), rabbit anti-goat IgG HRP conjugate (Upstate), anti-α-tubulin clone DM1A mouse antibody (1:10000; Upstate), anti-human MIF goat antibody (1:300–1:500; R&D Systems, Abingdon, UK), goat anti-mouse immunoglobulin (IgG, HRP conjugate (Upstate), anti-rabbit IgG HRP (R&D Systems) secondary antibodies.

**Sp1 inhibition assay**

CEMC7A were treated with mithramycin (Sigma) at 1 nM to 50 nM for 48 h, then analysed by Western blotting for endogenous MIF production. Alternatively, CEMC7A were treated with mithramycin at 200 nM for 24 h and transfected transiently with pGL3-control (which possesses an SV40 promoter and an SV40 enhancer), pGL3 promo/oligo-1 and pGL3. Cell death was analysed using Trypan blue exclusion (Sigma).

**Preparation of nuclear extract**

CEMC7A cells were grown to a density of 1 × 10⁶ cells/ml in 1 l of RPMI-1640 medium in order to gain a sufficient final volume of nuclear extract. Cells were harvested and washed twice in PBS. Nuclear extract was then prepared as described previously [27], with a minor modification. Cells were disrupted by passing the cell suspensions through a 23-gauge needle five times.

**Electrophoretic mobility shift assay (EMSA)**

EMSA was performed using a radiolabelled double-stranded DNA oligonucleotide corresponding to the intronic oligonucleotide sequence 1 (oligo-1), as described above.

The annealed oligonucleotide was end-labelled with [γ-32P]ATP (Amersham) using T4 polynucleotide kinase (Promega) and purified using G50 columns (Amersham).

Reactions contained 10 µl buffer C [10 mM Tris pH 7-8, 50 mM NaCl, 1 mM dithiothreitol (DTT), 1 mM EDTA 5% gycerol], 2 µg bovine serum albumin (BSA), 100 ng poly dI : dC, 0-1 ng labelled probe and 5 µg nuclear extract, as indicated in the figure legends. Competition experiments were performed by adding 100× unlabelled oligonucleotide to the reaction mixes prior to addition of radiolabelled probe, as indicated. Supershift experiments were performed by the addition of 2 µg of antibody as indicated prior to the addition of radiolabelled probe. Reactions were then incubated at room temperature for 1 h and loaded onto a 5% 0-5× TBE gel run at 150 V for approximately 3 h. Gels were then dried and autoradiographed.

**Bioinformatics**

To compare MIF DNA sequences across species, University of California Santa Cruz (UCSC) at http://genome.ucsc.edu and the NCBI at http://www.ncbi.nlm.nih.gov websites were used. Analysis of MIF intron 1 sequence for potential transcription factor sites was performed using the following database: AliBaba 2-1 and P-Match at http://www.gene-regulation.com and MatInspector from Genomatix at http://www.genomatix.de.

**Data analysis**

All luciferase results were adjusted to the CMV-renilla control and calculated as a fold induction relative to the control promoter. Statistical analysis was performed using spss version 11-5 or Prism 5. Multiple comparison analysis was performed using a one-way analysis of variance (ANOVA) with a post-hoc Bonferroni test and comparison of a group of data to a control group was performed using a one-way ANOVA comparative test with a post-hoc two-sided Dunnet’s t-test.
Results

DNase I hypersensitivity assay

Nuclei from a total of $10^8$ CEMC7A cells were isolated and treated with increasing amounts of DNase I. The genomic DNA was then isolated and restriction digested with BglII. This generated a 10·2 Kb fragment containing 3354 bp 5′ to the transcriptional start of the MIF gene and 5981 bp 3′ of the termination codon (Fig. 1b). Hybridization with a 468 bp probe specific to the 5′ end of the 10·2 Kb fragment revealed that it was digested by DNase I, indicating the presence of a hypersensitive site (HS). A shorter fragment of ~3·6 Kb appeared (Fig. 1a) as the DNase I concentration increased and interpolation of the band height of the ~3·6 Kb fragment indicated the HS spanned ~911 bp (Fig. 1b). The HS encompassed the first intron of MIF, which was isolated for further study.

The HS acts as an enhancer

The first intron of the MIF gene (containing the HS) was cloned into the pGL3 promoter vector, which contains an SV40 promoter upstream of the luciferase gene. MIF intron 1 was inserted at a site distal to the SV40 promoter in either the sense or anti-sense orientation (pGL3 SV40-MIF intron 1 sense/anti-sense). CEMC7A cells were then transfected with either pGL3 SV40-MIF intron 1 sense/anti-sense plasmids, or a pGL3 vector containing the SV40 promoter and SV40 enhancer (pGL3 SV40-SV40) or the SV40 promoter only (pGL3-SV40). Constructs were transfected transiently in CEMC7A cells, and luciferase gene expression was measured. The intron exhibited orientation-independent enhancer activity, showing a fivefold increase over the pGL3 promoter-only vector ($P < 0·0001$) (Fig. 2a).

The enhancer acts in a cell type-specific manner

In order to determine any cell type-specificity of intronic enhancer activity, HEK293T, SW982 (FLS), human RA FLS and THP-1 cells were transfected with constructs containing intron 1 of the MIF gene, in which luciferase gene transcription is initiated at the SV40 promoter. Enhancer activity was observed within the CEMC7A cells, as shown previously (Fig. 2a), with a fivefold induction above the SV40 promoter control ($P < 0·01$) (Fig. 2b). Enhanced transcriptional activity was also observed in HEK293T cells, with a sevenfold induction over the SV40 promoter ($P < 0·0001$) (Fig. 2b). However, no enhancer activity was noted in the FLS cell line SW982 and cultured RA FLS (Fig. 2b).

To assess if the intron had enhancer activity on the MIF promoter, the SV40 promoter was substituted for the full-length MIF promoter -1075 to +85 (CATT5) described previously [20]. The MIF promoter construct showed similar levels of transcriptional activation as the SV40 promoter control and this was consistent with all cell lines (Fig. 2b), with the exception of the THP-1 cell line, where enhanced transcriptional activity was detected when the MIF enhancer was coupled the MIF promoter ($P < 0·05$) but not with the SV40 promoter (Fig. 2b). This demonstrated that the intron could enhance the transcriptional activity of both a heterologous promoter or the MIF promoter in a cell type-specific manner, with a preference for the MIF promoter in THP-1 s, where no enhancer activity was detected with the SV40 promoter (Fig. 2b).

Mutation of Sp1 binding site abrogated enhancer activity

Comparative genomics combined with TF database analysis were used in order to identify potential TF for the enhancer
activity of the first intron of MIF. Search results suggested a high density of Sp1 binding sites in the 5' region of the MIF intron 1 (Fig. 3a). In order to determine a role for Sp1 in the enhancer activity of the HS, we cloned seven oligonucleotides of ~50 bp each, spanning the full length of the HS, at the enhancer site of the luciferase reporter vector pGL3, under the SV40 promoter, to determine the cis-acting elements in the enhancer (Fig. 3a). The reporter constructs were assayed in CEMC7A cells and oligo-1 and oligo-6 were shown to carry the cis elements responsible for the enhancer activity, as fold induction of luciferase activity over SV40-only control was increased significantly (oligo-1 P < 0.001, oligo-6 P < 0.05) (Fig. 3b). Oligos-2, -3, -4, -5 and -7 had no luciferase activity greater than that of the control (data not shown). Consensus binding site for Sp1 in oligo-1 and oligo-6 were mutated in order to disrupt Sp1 binding and the enhancer activity was assayed as per the WT oligonucleotides in CEMC7A cells (Fig. 3c). Disruption of the Sp1 consensus binding site in both oligo-1 and oligo-6 abrogated enhancer activity (oligo-1mut P < 0.001, oligo-6mut P < 0.01) (Fig. 3b), further suggesting a role for Sp1, or its family members, in driving the HS enhancer activity.

Sp1 binds the MIF enhancer

In order to determine whether Sp1 is recruited to the MIF intron 1 enhancer, EMSA was performed using CEMC7A nuclear extract and a radiolabelled DNA probe of the 5' region of the intronic sequence (oligo-1). We were able to demonstrate that Sp1 bound this sequence, as competition with excess cold Sp1 consensus sequence and addition of Sp1-specific antibody (aSP1) resulted in the abrogation of a shifted complex (Fig. 4). The 3' region of the intron also possessed putative Sp1 binding sites (oligo-6); however, no transcription factor binding to this sequence was observed using the same method (data not shown).

Knock-down of Sp1/Sp3 has no effect on enhancer activity

The presence of Sp1 in the different cell types in which the enhancer activity and Sp1 EMMA were studied was determined using immunoblots of whole cell lysates in untreated cells. In HEK293T and CEMC7A Sp1 was highly expressed, whereas THP-1 and FLS cells showed less expression (Fig. 5a). To analyse further the potential regulatory role of Sp1 in the enhancer function, RNA interference was used to deplete Sp1 in order to observe whether the enhancer activity was diminished. Western blotting showed that the endogenous Sp1 expression was knocked down in HEK293T cells.

© 2010 The Authors
Clinical and Experimental Immunology © 2010 British Society for Immunology, Clinical and Experimental Immunology, 163: 178–188
Fig. 5b). However, Sp1 knock-down had no effect on endogenous MIF expression (Fig. 5b).

Sp1 is part of a family of transcription factors (Sp1–Sp4) which share highly conserved DNA binding domains and can function co-operatively to regulate transcription of a multitude of genes [28]. Other members of the Sp1 family may be important in the control of the enhancer activity. Both Sp3 and Sp4 share high affinity for Sp1 consensus binding sites; however, Sp4 is expressed predominantly in the brain and shows limited expression in other tissues. Sp3 is expressed ubiquitously, therefore HEK293T cells were co-transfected with siRNA directed against Sp3 and Sp1 or lamin A/C as a negative control. Cells were harvested 48 h post-transfection and cell lysates analysed by Western blotting with anti-Sp1, anti-Sp3, anti-MIF and anti-tubulin antibodies. Both Sp1 and Sp3 showed a clear knock-down in HEK293T cells treated with Sp1 and Sp3 siRNA compared with cells treated with lamin siRNA (Fig. 5b,c). The prominent doublet at ~75 kDa (Sp3) was down-regulated markedly by siRNA; a higher molecular weight band (~100 kDa) is also Sp3-related and is knocked down by the siRNA (Fig. 5c). However, the knock-down of Sp1 and Sp3 in combination had no effect on endogenous MIF expression (Fig. 5c).

**Mithramycin specifically inhibits the enhancer activity**

In parallel to the Sp1/Sp3 knock-down assay and mutation analysis of the Sp1 binding sites in the cis-elements, the Sp1 inhibitor mithramycin was used to analyse further the role of Sp1 on the MIF intronic enhancer. CEMC7A cells were transfected transiently with luciferase reporter constructs containing wild-type (WT) or mutated oligo-1 or oligo-6 sequences. The pGL3 SV40 promoter-only construct was used as control and results are expressed as fold induction over the control. Following transfection, cells were incubated for 24 h before luciferase assays were performed. Results are representative of four to 10 independent experiments (± standard error of the mean) performed in single replicates. Results are expressed as a fold induction over the pGL3 SV40 or pGL3 MIF promoter vector. *P < 0.05; **P < 0.01; ***P < 0.001. (c) Sp1 binding site mutation. Three base pairs in each Sp1 consensus binding site were mutated from G to T, disrupting the core element for Sp1 binding.

---

E. Beaulieu et al., Clinical and Experimental Immunology © 2010 The Authors Clinical and Experimental Immunology © 2010 British Society for Immunology, Clinical and Experimental Immunology, 163: 178–188
Fig. 4. Sp1 binds MIF intron 1. Electrophoretic mobility shift assay (EMSA) analysis demonstrating the binding of Sp1 to oligo-1. Nuclear extracts prepared from CEMC7A cells were incubated with radiolabelled oligo-1. Competition experiments were performed by the addition of 100× unlabelled oligonucleotide (cold Sp1) as indicated; 2 μg of rabbit IgG or Sp1 antibody added as indicated. Complexes were then resolved by native gel electrophoresis. Sp1 sequence specific complex marked by an arrow.

Discussion

This study aimed to expand the understanding of MIF gene regulation in cell types of relevance to inflammatory pathologies such as RA.

DNase I treatment revealed a strong HS centred on the first intron of MIF. The intronic constructs examined showed strong enhancer activity in the CEMC7A cells, regardless of orientation, suggesting classical enhancer activity [29,30]. This enhancer was cell type-specific, with enhancer activity observed in immune cells, namely a T lymphoblast and a monocytic cell line, but not in cells from mesenchymal origin (SW982 and cultured RA FLS), poten-
Mithramycin inhibits endogenous expression of MIF in CEMC7A cells. CEMC7A cell were transfected transiently either with a control vector possessing the SV40 promoter (control) or a vector containing oligo-1 or oligo-6. The cells were then treated with 200 nM mithramycin and left to incubate for 24 h. Cell lysates were then collected and immunoblotted with the relevant primary sera: anti-MIF goat antibody for MIF and anti-alpha-tubulin clone DM1A mouse antibody for tubulin. Cell death was counted by trypan blue exclusion. Results are representative of a minimum of two independent experiments (±standard error of the mean) performed in biological triplicates. Results are expressed as fold induction over the untreated control vector. *P < 0.05; **P < 0.01.

(b) Mithramycin inhibits endogenous expression of MIF in CEMC7A cells. CEMC7A cells were treated with increasing amounts of mithramycin (0, 1, 10 and 50 nM) for 24 h. Cell lysates were then collected and immunoblotted with the relevant primary anti-sera: anti-MIF goat antibody for MIF and anti-alpha-tubulin clone DM1A mouse antibody for tubulin. Cell death was counted by trypan blue exclusion. Results are representative of three independent experiments performed in biological triplicates. Results are expressed as fold induction over untreated cells.

Mithramycin specifically inhibits the enhancer activity and endogenous migration inhibitory factor (MIF) expression. (a) Mithramycin inhibits the enhancer activity in CEMC7A cells. CEMC7A cells were transfected transiently either with a control vector possessing the SV40 promoter (control) or a vector containing oligo-1 or oligo-6. The cells were then treated with 200 nM mithramycin and left to incubate for 24 h. In untreated cells (white columns), the oligo-1 and oligo-6 reporter assays show enhancer activity. This activity was abrogated by the addition of mithramycin to the cells (black columns). Results are representative of a minimum of two independent experiments (±standard error of the mean) performed in biological triplicates. Results are expressed as fold induction over the untreated control vector. *P < 0.05; **P < 0.01.

(b) Mithramycin inhibits endogenous expression of MIF in CEMC7A cells. CEMC7A cells were treated with increasing amounts of mithramycin (0, 1, 10 and 50 nM) for 24 h. Cell lysates were then collected and immunoblotted with the relevant primary anti-sera: anti-MIF goat antibody for MIF and anti-alpha-tubulin clone DM1A mouse antibody for tubulin. Cell death was counted by trypan blue exclusion. Results are representative of three independent experiments performed in biological triplicates. Results are expressed as fold induction over untreated cells.

(c) Mithramycin inhibits the enhancer activity of the MIF promoter. CEMC7A cell were transfected with the MIF promoter only plasmid (MIF promo) and were left untreated (white column) or were treated with 200 nM mithramycin (black column) and left to incubate 24 h before luciferase assay was performed. Results are representative of two independent experiments performed in biological triplicates. Results are expressed as fold induction over untreated cells.

Mithramycin inhibits endogenous expression of MIF in CEMC7A cells. CEMC7A cells were treated with increasing amounts of mithramycin (0, 1, 10 and 50 nM) for 24 h. Cell lysates were then collected and immunoblotted with the relevant primary sera: anti-MIF goat antibody for MIF and anti-alpha-tubulin clone DM1A mouse antibody for tubulin. Cell death was counted by trypan blue exclusion. Results are characteristic of a minimum of two independent experiments (±standard error of the mean) performed in biological triplicates. Results are expressed as fold induction over the untreated control vector. *P < 0.05; **P < 0.01.

(b) Mithramycin inhibits endogenous expression of MIF in CEMC7A cells. CEMC7A cells were treated with increasing amounts of mithramycin (0, 1, 10 and 50 nM) for 24 h. Cell lysates were then collected and immunoblotted with the relevant primary sera: anti-MIF goat antibody for MIF and anti-alpha-tubulin clone DM1A mouse antibody for tubulin. Cell death was counted by trypan blue exclusion. Results are representative of a minimum of two independent experiments (±standard error of the mean) performed in biological triplicates. Results are expressed as fold induction over the untreated control vector. *P < 0.05; **P < 0.01.

(c) Mithramycin inhibits the enhancer activity of the MIF promoter. CEMC7A cell were transfected with the MIF promoter only plasmid (MIF promo) and were left untreated (white column) or were treated with 200 nM mithramycin (black column) and left to incubate 24 h before luciferase assay was performed. Results are characteristic of two independent experiments performed in biological triplicates. Results are expressed as fold induction over untreated cells.

Mithramycin specifically inhibits the enhancer activity and endogenous migration inhibitory factor (MIF) expression. (a) Mithramycin inhibits the enhancer activity in CEMC7A cells. CEMC7A cells were transfected transiently either with a control vector possessing the SV40 promoter (control) or a vector containing oligo-1 or oligo-6. The cells were then treated with 200 nM mithramycin and left to incubate for 24 h. In untreated cells (white columns), the oligo-1 and oligo-6 reporter assays show enhancer activity. This activity was abrogated by the addition of mithramycin to the cells (black columns). Results are characteristic of two independent experiments performed in biological triplicates. Results are expressed as fold induction over the untreated control vector. *P < 0.05; **P < 0.01.

(b) Mithramycin inhibits endogenous expression of MIF in CEMC7A cells. CEMC7A cells were treated with increasing amounts of mithramycin (0, 1, 10 and 50 nM) for 24 h. Cell lysates were then collected and immunoblotted with the relevant primary sera: anti-MIF goat antibody for MIF and anti-alpha-tubulin clone DM1A mouse antibody for tubulin. Cell death was counted by trypan blue exclusion. Results are characteristic of two independent experiments performed in biological triplicates. Results are expressed as fold induction over the untreated control vector. *P < 0.05; **P < 0.01.

(c) Mithramycin inhibits the enhancer activity of the MIF promoter. CEMC7A cell were transfected with the MIF promoter only plasmid (MIF promo) and were left untreated (white column) or were treated with 200 nM mithramycin (black column) and left to incubate 24 h before luciferase assay was performed. Results are characteristic of two independent experiments performed in biological triplicates. Results are expressed as fold induction over untreated cells.

Mithramycin specifically inhibits the enhancer activity and endogenous migration inhibitory factor (MIF) expression. (a) Mithramycin inhibits the enhancer activity in CEMC7A cells. CEMC7A cells were transfected transiently either with a control vector possessing the SV40 promoter (control) or a vector containing oligo-1 or oligo-6. The cells were then treated with 200 nM mithramycin and left to incubate for 24 h. In untreated cells (white columns), the oligo-1 and oligo-6 reporter assays show enhancer activity. This activity was abrogated by the addition of mithramycin to the cells (black columns). Results are characteristic of two independent experiments performed in biological triplicates. Results are expressed as fold induction over the untreated control vector. *P < 0.05; **P < 0.01.
between Sp1, Sp3 and other members of the Sp family has been described previously [42,43], and as such these remain possible interaction partners for Sp1 and could influence MIF enhancer function.

To determine the physiological relevance of the enhancer, CEMC7A cells were treated with increasing concentrations of mithramycin, and comparison of MIF protein expression between treated and untreated cells was undertaken. Clearly, endogenous MIF production was inhibited after treating CEMC7A cells with 10 nM of mithramycin for 48 h (Fig. 5). Importantly, the inhibitory effect of mithramycin on MIF production was specific to the enhancer activity, as mithramycin had no effect on the MIF promoter itself, despite its high GC content, and the presence of a number of putative Sp1 sites.

Roger et al. found that mithramycin inhibited the transcriptional activity of a MIF promoter reporter assay and MIF mRNA expression in monocytic THP-1 cells [44]. We have looked at the effects of mithramycin in a different cell type, a T lymphoblastic cell line, CEMC7A, and found no effect of mithramycin on the MIF promoter but inhibition of the MIF intronic enhancer. These observations show that mithramycin, albeit potentially through different mechanisms, plays an immunosuppressive role on immune cells via the down-regulation of MIF.

As an anti-neoplastic drug, the role of mithramycin in apoptosis [45] and in inflammation has been investigated previously [46]. Mithramycin has also been shown to inhibit bone resorption [47]. Analogues of mithramycin have been developed recently which have enhanced efficacy and specificity [48,49]. Use of such drugs for the selective reduction of MIF in circulating immune cells could enhance the therapeutic advantage of glucocorticoids, which has important implications in the long-term management of chronic inflammatory conditions such as RA.

Acknowledgements

We are grateful to Dr May Tassabehji for expert help with Southern blotting. The authors’ laboratories are supported by the Manchester Academic Health Sciences Centre (MAHSC), the NIHR Biomedical Research Centre and by the National Health and Medical Research Council of Australia. This work was supported by grants from the Arthritis Research Campaign, UK and the NHMRC, Australia. E. B. is a recipient of a Frederick Craven Fellowship Award.

Disclosure

The authors have nothing to declare.

References

1 Calandra T, Bernhagen J, Mitchell RA, Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994; 179:1895–902.

2 Bernhagen J, Calandra T, Mitchell RA et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 1993; 365:756–9.

3 Bernhagen J, Bacher M, Calandra T et al. An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. J Exp Med 1998; 183:277–82.

4 Kudrin A, Scott M, Martin S et al. Human macrophage migration inhibitory factor: a proven immunomodulatory cytokine. J Biol Chem 2006; 281:29641–51.

5 Mikulowska A, Metz CN, Bucala R, Holmdahl R. Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. J Immunol 1997; 158:5514–17.

6 Leech M, Metz C, Santos L et al. Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis Rheum 1998; 41:910–17.

7 Santos L, Hall P, Metz C, Bucala R, Morand EF. Role of macrophage migration inhibitory factor (MIF) in murine antigen-induced arthritis: interaction with glucocorticoids. Clin Exp Immunol 2001; 123:309–14.

8 Leech M, Lacey D, Xue JR et al. Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis. Arthritis Rheum 2003; 48:1881–9.

9 Santos LL, Dacumos A, Yamana J, Sharma L, Morand EF. Reduced arthritis in MIF deficient mice is associated with reduced T cell activation: down-regulation of ERK MAP kinase phosphorylation. Clin Exp Immunol 2008; 152:372–80.

10 Leech M, Metz C, Hall P et al. Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum 1999; 42:1601–8.

11 Onodera S, Tanji H, Suzuki K et al. High expression of macrophage migration inhibitory factor in the synovial tissues of rheumatoid joints. Cytokine 1999; 11:163–7.

12 Onodera S, Kaneda K, Mizue Y, Koyama Y, Fujinaga M, Nishihira J. Macrophage migration inhibitory factor up-regulates expression of matrix metalloproteinases in synovial fibroblasts of rheumatoid arthritis. J Biol Chem 2000; 275:444–50.

13 Onodera S, Suzuki K, Matsuno T, Kaneda K, Kuriyama T, Nishihira J. Identification of macrophage migration inhibitory factor in murine neonatal calvariae and osteoblasts. Immunology 1996; 89:430–5.

14 Pakozdi A, Amin MA, Haas CS et al. Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritis. Arthritis Res Ther 2006; 8R132.

15 Onodera S, Oshima S, Nishihira J et al. Active immunization against macrophage migration inhibitory factor using a novel DNA vaccine prevents ovariectomy-induced bone loss in mice. Vaccine 2008; 26:829–36.

16 Onodera S, Sasaki S, Ohshima S et al. Transgenic mice overexpressing macrophage migration inhibitory factor (MIF) exhibit high-turnover osteoporosis. J Bone Miner Res 2006; 21:876–83.

17 Roger T, Chanson AL, Knaup-Reymond M, Calandra T. Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. Eur J Immunol 2005; 35:3405–13.

18 Aeberli D, Leech M, Morand EF. Macrophage migration inhibitory factor and glucocorticoid sensitivity. Rheumatology (Oxf) 2006; 45:937–43.
19 Calandra T, Bernhagen J, Metz CN et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995; 377:68–71.

20 Alourfi Z, Donn RP, Stevens A, Berry A, McMaster A, Ray DW. Glucocorticoids suppress macrophage migration inhibitory factor (MIF) expression in a cell-type specific manner. J Mol Endocrinol 2005; 34:583–95.

21 Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003; 3:791–800.

22 Baugh JA, Gantier M, Li L, Byrne A, Buckley A, Donnelly SC. Dual regulation of macrophage migration inhibitory factor (MIF) expression in hypoxia by CREB and HIF-1. Biochem Biophys Res Commun 2006; 347:895–903.

23 Welford SM, Bedogni B, Gradin K, Poellinger L, Broome PM, Giaccia AJ. HiFI[alpha] delays premature senescence through the activation of MIF. Genes Dev 2006; 20:3366–71.

24 Elsbry LM, Donn RP, Alourfi Z, Green LM, Beaulieu E, Ray DW. Hypoxia and glucocorticoid signalling converge to regulate MIF gene expression. Arthritis Rheum 2009; 61:3220–31.

25 Weber G, Thompson N, Chautard T et al. Transcriptional activation of the macrophage migration-inhibitory factor gene by the corticortin-releasing factor is mediated by the cyclic adenosine 3',5'-monophosphate responsive element-binding protein CREB in pituitary cells. Mol Endocrinol 1998; 12:698–705.

26 Donn R, Berry A, Stevens A et al. Use of gene expression profiling to identify a novel glucocorticoid sensitivity determining gene, BMPRII. FASEB J 2007; 21:402–14.

27 Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucl Acids Res 1983; 11:1745–89.

28 Wiersma I. Sp1: emerging roles – beyond constitutive activation of TATA-less housekeeping genes. Biochem Biophys Res Commun 2008; 372:1–13.

29 Blackwood EM, Kadonaga JT. Going the distance: a current view of transcriptional regulation of the dihydrofolate-reductase gene in vivo. J Clin Invest 1991; 88:1613–21.

30 Ray R, Snyder RC, Thomas S, Koller CA, Miller DM. Mithramycin blocks protein-binding and function of the Sp40 early promoter. J Clin Invest 1989; 83:2003–7.

31 Safe S, Kim K. Nuclear receptor-mediated transactivation through G-C containing Dna. Am J Med Sci 1987; 294:388–94.

32 Safe S, Abdelrahim M. Sp transcription factor family and its role in cell growth and differentiation. Cell 1997; 89:619–28.

33 Koller CA, Miller DM. Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic-leukemia with plicamycin and hydroxyurea. N Engl J Med 1986; 315:1433–8.

34 Dutcher JP, Coletti D, Piaietta E, Wierink PH. A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia. Leuk Res 1997; 21:375–80.

35 Blume SW, Snyder RC, Ray R, Thomas S, Koller CA, Miller DM. Mithramycin inhibits Sp1 binding and selectively inhibits transcriptional activity of the dihydrofolate-reductase gene in vitro and in vivo. J Clin Invest 1991; 88:1613–21.

36 Calandra T, Bernhagen J, Metz CN et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995; 377:68–71.

37 Lombo F, Menendez N, Salas JA, Mendez C. The aureolic acid mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy. Nucl Acids Res 2006; 34:1721–34.